Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 21 | Rare Historical Photos

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Benzinga

Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come.

Benzinga

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators

The Independent UK

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Benzinga

AstraZeneca To Invest $50 Bn In The US As Tariff Threat Looms

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid Donald Trump's threats to impose tariffs on the sector.

International Business Times

AstraZeneca pledges $50bn US investment ahead of drugs tariffs

Donald Trump is expected to announce tariffs of up to 200% on drugs makers in August

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats

UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US

The Guardian - UK

Rachel Reeves vows to stick to fiscal rules and declines to rule out wealth tax – as it happened

Rolling coverage of the latest economic and financial news, as chancellor Rachel Reeves testifies to House of Lords economic affairs committee

The Guardian - UK

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets

On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.

Benzinga

Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety

A group of employees from Theramex, which supplies HRT treatments to millions of patients in the UK, wrote a letter to the pharmaceutical regulator

The Independent UK

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Benzinga

FDA names former pharmaceutical company executive to oversee US drug program

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program

The Independent UK

3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags

According to the technical analysis of over 4,400 publicly traded U.S. companies with a market cap exceeding $100 million, three firms signal a potential trend reversal amid overbought conditions.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

The ground shook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) last week as the U.S. Food and Drug Administration (FDA), alarmed by a third patient death tied to its gene therapy platform, pulled a rare move: requesting a voluntary halt to Elevidys shipments. The company’s response? A resounding “no,” igniting a major…

The Independent UK

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy

Benzinga

The Vaping Giant That Almost Died: JUUL's Shocking FDA Reversal

In a significant reversal and a major boost for the embattled vaping company, the U.S. Food and Drug Administration (FDA) on Thursday authorized the marketing of five JUUL Labs Inc. e-cigarette products, including the JUUL device and its Virginia Tobacco and Menthol flavored JUULpods in both 3% and 5% nicotine…

Benzinga

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced its voluntary delisting from the Nasdaq Capital Market.

International Business Times

US Authorizes Juul To Market Vaping Products

Juul Labs said Thursday that the US Food and Drug Administration had officially authorized the e-cigarette maker to market its vaping system and refill capsules in the United States.

Benzinga

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Benzinga

Centene Stock Hit A New 52-Week Low Today: What's Going On?

Shares of Centene Corp (NYSE:CNC) are trading lower on Thursday, hitting a new 52-week low, as worsening news from a key competitor intensified investor fears about the profitability of government-sponsored health plans.

Benzinga

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market trading after the company announced it will engage in strategic restructuring and cost savings.

Benzinga

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

214 stories

Biogen

207 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.